

Kenneth C Kalunian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7305608/publications.pdf>

Version: 2024-02-01

87
papers

6,671
citations

186265
28
h-index

110387
64
g-index

94
all docs

94
docs citations

94
times ranked

5493
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Oral Contraceptives in Women with Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2005, 353, 2550-2558.	27.0	962
2	Anifrolumab, an Anti-Interferon- γ Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 376-386.	5.6	634
3	The Effect of Combined Estrogen and Progesterone Hormone Replacement Therapy on Disease Activity in Systemic Lupus Erythematosus: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2005, 142, 953.	3.9	539
4	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019, 20, 902-914.	14.5	501
5	Sifalimumab, an anti-interferon- γ monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1909-1916.	0.9	420
6	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , The, 2018, 392, 222-231.	13.7	396
7	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
8	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
9	A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon- γ) in patients with systemic lupus erythematosus (ROSE). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 196-202.	0.9	302
10	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.9	266
11	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. <i>Lancet Rheumatology</i> , The, 2019, 1, e208-e219.	3.9	250
12	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-blind, Placebo-controlled Trials. <i>Arthritis and Rheumatology</i> , 2017, 69, 362-375.	5.6	189
13	Clinical significance of a single test for anti-cardiolipin antibodies in patients with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1988, 85, 602-608.	1.5	154
14	Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 883-889.	0.9	107
15	Validation of American College of Rheumatology Classification Criteria for Knee Osteoarthritis Using Arthroscopically Defined Cartilage Damage Scores. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 35, 197-201.	3.4	97
16	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
17	Antinuclear Antibody-negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70
18	Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008, 58, 1784-1788.	6.7	66

#	ARTICLE	IF	CITATIONS
19	Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. <i>Lupus Science and Medicine</i> , 2014, 1, e000056.	2.7	65
20	Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. <i>Arthritis Research and Therapy</i> , 2008, 10, R105.	3.5	63
21	CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 603-610.	1.9	60
22	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
23	Work disability, lost productivity and associated risk factors in patients diagnosed with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2015, 2, e000058-e000058.	2.7	47
24	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
25	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
26	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
27	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 951-961.	0.9	38
28	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
29	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	2.7	31
30	New directions in the treatment of systemic lupus erythematosus. <i>Current Medical Research and Opinion</i> , 2009, 25, 1501-1514.	1.9	30
31	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
32	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
33	Multi-cell type gene coexpression network analysis reveals coordinated interferon response and cross-cell type correlations in systemic lupus erythematosus. <i>Genome Research</i> , 2021, 31, 659-676.	5.5	23
34	Idiotypic spreading promotes the production of pathogenic autoantibodies. <i>Journal of Autoimmunity</i> , 1988, 1, 47-61.	6.5	19
35	Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2016, 3, e000165.	2.7	18
36	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018, 5, e000263.	2.7	18

#	ARTICLE	IF	CITATIONS
37	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
38	Arthroscopic synovectomy by rheumatologists: Time for a new look. <i>Arthritis and Rheumatism</i> , 1989, 32, 108-111.	6.7	16
39	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 962-969.	0.9	15
40	Idiotypic characteristics of immunoglobulins associated with human systemic lupus erythematosus: association of high serum levels of IgG2 with nephritis but not with HLA class II genes predisposing to nephritis. <i>Arthritis and Rheumatism</i> , 1990, 33, 978-984.	6.7	13
41	Preferential recognition of a fragment species of osteoarthritic synovial fluid fibronectin by antibodies to the alternatively spliced EIIIA segment. <i>Arthritis and Rheumatism</i> , 2001, 44, 2572-2585.	6.7	12
42	Immunosuppressant use and hospitalisations in adult patients with systemic lupus erythematosus admitted to a tertiary academic medical centre. <i>Lupus Science and Medicine</i> , 2018, 5, e000249.	2.7	11
43	Arthroscopy in rheumatology: where have we been? Where might we go?. <i>Rheumatology</i> , 2021, 60, 518-528.	1.9	10
44	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
45	Combined Oral Contraceptives in Women With Systemic Lupus Erythematosus. <i>Obstetrical and Gynecological Survey</i> , 2006, 61, 251-253.	0.4	8
46	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8
47	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021, 8, e000433.	2.7	7
48	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
49	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. <i>Lancet Rheumatology</i> , The, 2022, 4, e198-e207.	3.9	7
50	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	3.4	7
51	Evaluating duration of response to treatment in systemic lupus erythematosus clinical trials. <i>Lupus Science and Medicine</i> , 2018, 5, e000266.	2.7	6
52	Prevalence of Crystals in Knee Osteoarthritis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 51-53.	0.9	6
53	Why Not Wash Out the Osteoarthritic Knee?. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 43-45.	0.9	6
54	High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. <i>Rheumatology</i> , 2022, 61, 4335-4343.	1.9	6

#	ARTICLE	IF	CITATIONS
55	Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. <i>Lupus Science and Medicine</i> , 2021, 8, e000522.	2.7	5
56	Will rheumatologists ever pick up the arthroscope again?. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1235-1246.	1.9	4
57	An ACVR1 R375P pathogenic variant in two families with mild fibrodysplasia ossificans progressiva. <i>American Journal of Medical Genetics, Part A</i> , 2021, , .	1.2	3
58	Is it time to bring back knee washout?. <i>Journal of Rheumatology</i> , 2022, , jrheum.211132.	2.0	3
59	Arthroscopy in Rheumatology: Time for a New Look?. <i>Journal of Rheumatology</i> , 2018, 45, 300-301.	2.0	2
60	FRI0154â€¦SAFETY AND EFFICACY OF FILGOTINIB IN PATIENTS AGED 65 YEARS AND OLDER: RESULTS FROM A PHASE 3 STUDY IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		2
61	199â€¦Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study. , 2019, , .		2
62	Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. <i>Kidney International Reports</i> , 2020, 5, 1302-1305.	0.8	2
63	Idiotype selection is an immunoregulatory mechanism which contributes to the pathogenesis of systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1988, 1, 673-681.	6.5	1
64	P216â€¦Effects of filgotinib on anaemia, thrombocytopenia and leukopenia: results from a Phase 3 study in patients with active RA and prior inadequate response or intolerance to bDMARDs. <i>Rheumatology</i> , 2020, 59, .	1.9	1
65	Arthroscopy in Rheumatology. <i>Arthroscopy - Journal of Arthroscopic and Related Surgery</i> , 2021, 37, 1364-1365.	2.7	1
66	Monitoring Disease Activity. , 2011, , 697-705.		0
67	Design of Clinical Trials for SLE. , 2011, , 719-726.		0
68	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
69	CT-06â€¦Missing outcomes in SLE clinical trials: impact on estimating treatment effects. , 2018, , .		0
70	O86â€¦Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs. <i>Rheumatology</i> , 2019, 58, .	1.9	0
71	THU0173â€¦FILGOTINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR) BY RACE & GEOGRAPHIC REGION. , 2019, , .		0
72	FRI0092â€¦SAFETY AND EFFICACY OF FILGOTINIB IN ACTIVE RHEUMATOID ARTHRITIS BY PRIOR BIOLOGICAL DMARD EXPOSURE IN PATIENTS WITH PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGICAL DMARDS (BDMARD-IR). , 2019, , .		0

#	ARTICLE	IF	CITATIONS
73	OPO252â€¦NEUROPATHIES IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM AN INTERNATIONAL, INCEPTION COHORT STUDY. , 2019, , .		0
74	AB0448â€¦SAFETY AND EFFICACY OF FILGOTINIB IN JAPANESE PATIENTS ENROLLED IN A GLOBAL PHASE 3 TRIAL OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC DMARDS. , 2019, , .		0
75	237â€¦Cell bound complement activation products in combination with low complement C3 or C4 have high diagnostic yield in systemic lupus erythematosus. , 2019, , .		0
76	P186â€¦Early and sustained responses with anifrolumab in patients with systemic lupus erythematosus (SLE) in 2 phase 3 trials. , 2020, , .		0
77	MO007A PHASE 1B MULTIPLE ASCENDING-DOSE STUDY OF A CD6 TARGETED THERAPY, ITOLIZUMAB, IN SUBJECTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WITH OR WITHOUT ACTIVE PROLIFERATIVE LUPUS NEPHRITIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
78	Monitoring disease activity. , 2021, , 407-422.		0
79	SLE-Associated Tests. , 2005, , 210-220.		0
80	Idiotype Selection is an Immunoregulatory Mechanism which Contributes to the Pathogenesis of Systemic Lupus Erythematosus. , 1989, , 177-185.		0
81	Definition, Classification, Activity and Damage Indices in Systemic Lupus Erythematosus. , 2019, , 328-338.		0
82	1124â€¦Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
83	1107â€¦Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0
84	801â€¦Factors associated with SLE flares after HCQ taper, discontinuation or maintenance in the SLICC inception cohort: lower education linked with higher flare risk. , 2021, , .		0
85	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
86	Regarding Arthroscopy. Journal of Clinical Rheumatology, 2022, 28, 177-181.	0.9	0
87	Matrix Metalloproteinase Inhibitors as Therapies for Rheumatoid Arthritis. , 0, , 135-145.		0